Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Nucleophosmin-1 mutations (NPM1(+)) occur in ∼30% of acute myeloid leukemia (AML) patients. Although typically associated with favorable prognosis, the beneficial impact of NPM1(+) decreases with increasing age in patients treated with standard intensive chemotherapy (IC) or hypomethylating agents (...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Autores principales: Lachowiez, Curtis A., Loghavi, Sanam, Kadia, Tapan M., Daver, Naval, Borthakur, Gautam, Pemmaraju, Naveen, Naqvi, Kiran, Alvarado, Yesid, Yilmaz, Musa, Short, Nicholas, Ohanian, Maro, Pierce, Sherry R., Patel, Keyur P., Qiao, Wei, Ning, Jing, Sasaki, Koji, Takahashi, Koichi, Jabbour, Elias, Andreeff, Michael, Ravandi, Farhad, Kantarjian, Hagop M., Konopleva, Marina, DiNardo, Courtney D.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2020
Materias:
Myeloid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7160266/
https://ncbi.nlm.nih.gov/pubmed/32251497
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001267
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares